Correvio Pharma — Investor Presentation (November 2019)
14 slides from Correvio Pharma's investor presentation, November 2019
Slide 1: Corporate Presentation
Corporate Presentation November 2019 NASDAQ: CORV / TSX: CORV
Slide 2: Forward Looking Statement Disclaimer
Forward Looking Statement Disclaimer ● Certain statements in this presentation contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” under applicable Canadian securities legislation (collectively, "forwar
Slide 3: Correvio Summary
Correvio Summary Brinavess - NDA-stage acute care An established, product, with a potential ~$500M US fully-integrated company, dollar market opportunity, ~20% with a large US penetration of total US atrial cardioversion opportunity fibrillation patient population Generated $21.3M in YTD revenue Suf
Slide 4: Executing on Final Regulatory Steps
Executing on Final Regulatory Steps ● Following Type C meeting with FDA Correvio resubmitted Brinavess NDA in Q2 2019 ● Resubmission accepted by FDA in July 2019 ● FDA Advisory Committee scheduled for December 10, 2019 ● PDUFA target action date of December 24, 2019 ● Eligible to apply for formal pa
Slide 5: A Strong Body of Real-World Data
A Strong Body of Real-World Data SPECTRUM 34 ISTs and Other Post- 59K Approval Studies ● Post authorization safety study (EU) ● Brinavess has been the subject of ● Over 8 years of real-world ● 1,778 unique patients with 2,009 treatment experience from over 59,000 episodes at 53 centers in 6 countrie
Slide 6: Expanding Physician Awareness
Expanding Physician Awareness ACC 2020 JACC AHA 2019 Planning for a strong Manuscript submitted presence at the Presented Post hoc analysis of to a prestigious U.S. upcoming American SPECTRUM data SPECTRUM patients medical journal for College of Cardiology at the upcoming specifically treated in the
Slide 7: SPECTRUM at AHA 2019: New SPECTRUM Data Presented at AHA 2019
SPECTRUM at AHA 2019 New SPECTRUM Data Presented at AHA 2019 ● New post hoc analysis data ● 1,289 unique patients treated specifically in the ER ● 70.2% efficacy with 12-minute median time to conversion ● Median length of hospital stay was 7.5 hours; only 13% of patients were in hospital for >24 hou
Slide 8: U.S. Market Opportunity – Key Research Findings
U.S. Market Opportunity – Key Research Findings 7.1M >500K 10 years >$1B Prevalence of Atrial Cardioversions First New Treatment $1B Addressable Fibrillation Performed in 10 Years Market Growing to $1.9B by 2030 7.1 million unique According to actual claims If approved, Brinavess will Independent re
Slide 9: EU Marketed Products and Major Regulatory Decisions Upcoming
4 EU Marketed Products and 2 Major Regulatory Decisions Upcoming $21.3M in YTD revenue through September 30, 2019; +8% vs same period in 2018 Product Brand Therapeutic Area Partner / Innovator Product Positioning • 60+ countries Cardiovascular via Correvio • Limited/no promotion (genericized) • Nord
Slide 10: United Therapeutics Trevyent Update
United Therapeutics Trevyent® Update ✓ FDA has accepted United Therapeutics’ (NASDAQ: UTHR) Trevyent NDA ✓ Assigned a PDUFA date of April 27, 2020 ▪ Correvio plans to submit a regulatory filing for TREVYENT in Europe in second half of 2020 “[Trevyent] is going to be “…truly a plug-and-play system.”
Slide 11: Progress and Brinavess Milestones
Progress and Brinavess Milestones 2019 2020 Q2 Q3 Q4 Q1 Q2 2019: Q3 2019: Q3 2019: Q4 2019: Q4 2019: Q4 2019: H1 2020: NDA NDA ESC 2019 Regulatory FDA PDUFA/ Potential re-submission acceptance SPECTRUM data clarity from Advisory FDA US to FDA presented at the China FDA Committee decision partnership
Slide 12: Q3 2019 Financials
Q3 2019 Financials $13.8M $10M $19.7M 50.5M Equity financing in Up to an additional As of September 30, Shares outstanding August 2019 adds $10M available 2019, cash, cash (as of November 13, 2019) gross proceeds of from CRG equivalents, and $13.8M restricted cash of $19.7M 12 | CORREVIO PRESENTATIO
Slide 13: Correvio Summary
Correvio Summary Brinavess - NDA-stage acute care An established, product, with a potential ~$500M US fully-integrated company, dollar market opportunity, ~20% with a large US penetration of total US atrial cardioversion opportunity fibrillation patient population Generated $21.3M in YTD revenue Suf
Slide 14: Thank You!
Thank You! Investor Contacts Brendan Payne Argot Partners Assoc. Dir., Investor Relations Michelle Carroll/Claudia Styslinger and Business Development 212.600.1902 Correvio Pharma Corp. michelle@argotpartners.com 604.677.6905 ext. 306 claudia@argotpartners.com 800.330.9928 bpayne@correvio.com NASDAQ
Correvio Pharma — Investor Presentation (November 2019) on 6ix